Skip to content

Frontlight ResearchEarly access

Trial site

Ajou University Hospital

Suwon, 16499, South KoreaNot linked to an institution yet

106running trials
42closed trials

The trials here

What the 148 trials at this site are about, from their registry records.

Conditions: Lung cancer30 trials
Coronary artery disease13 trials
Gastric and oesophageal cancer8 trials
Metastatic breast cancer8 trials
Lupus (SLE)7 trials
Head and neck cancer6 trials
Obesity6 trials
Ovarian cancer6 trials
Type 2 diabetes6 trials
Alzheimer disease5 trials
IgA nephropathy5 trials
Atrial fibrillation4 trials
and 40 more
Phase: Phase 373 trials
Phase 225 trials
Phase 2/310 trials
Phase 18 trials
Phase 48 trials
Phase 1/25 trials
Status: Active, not recruiting50 trials
Recruiting41 trials
Completed37 trials
Not yet recruiting11 trials
Enrolling by invitation4 trials
Terminated4 trials
Withdrawn1 trial
Lead sponsor: Eli Lilly and Company12 trials
Janssen Research & Development, LLC10 trials
Boehringer Ingelheim6 trials
Pfizer6 trials
BioNTech SE5 trials
and 70 more

Running trials

Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
NCT07768189· Phase 3· Corbus Pharmaceuticals Inc.· Source
Contact: Clinical Study Coordinator
Recruiting
Optimal Timing of Staged Complete Revascularization in STEMI With Multivessel Disease (OPTION-STEMI2)
NCT07741721· Chonnam National University Hospital· Source
Contact: Min Chul Kim, MD, PhD
Recruiting
STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure
NCT07631156· Phase 4· Kyungsub Song· Source
Contact: Soo Jin Park, MD/PhD
Not yet recruiting
Functional And STructural Assesment of the Heart by Artificial Intelligence-enabled Electrocardiogram for the Management of Atrial Fibrillation
NCT07486739· Seoul National University Hospital· Source
Contact: Do-Young Kim
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
NCT07516951· Phase 2· Chiesi Farmaceutici S.p.A.· Source
Contact: Joo Hun Park
Recruiting
The STem Cell-derived Extracellular Vesicle Therapy In Acute Ischemic Stroke (STEVIA)
NCT06995625· Phase 1· S&Ebio Co. Ltd.· Source
Contact: Jin soo Lee, MD (principal investigator)
Recruiting
Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study
NCT07572032· Phase 4· Kyungsub Song· Source
Contact: Soo Jin Park, MD/PhD
Recruiting
Artificial Intelligence-Driven Medipixel Fractional Flow Reserve Versus Invasive Fractional Flow Reserve-Guided PCI Trial (AIM-FFR Trial)
NCT07329699· Samsung Medical Center· Source
Contact: Hong-Seok Lim, MD,PhD
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· Phase 3· Incyte Corporation· Source
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Hyun Woo Lee, Site 0571
Recruiting
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199· Phase 3· Taiho Oncology, Inc.· Source
Contact: Taiho Oncology, Inc.
Enrolling by invitation
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT07256392· Phase 3· Celldex Therapeutics· Source
Recruiting
AI-Based Prediction of Atrial Fibrillation in ESUS Patients With ICM
NCT07347691· Inha University Hospital· Source
Contact: Jihee Kang
Enrolling by invitation
WEgovy Real World Assessment of Weight Loss in Korea
NCT07280221· Novo Nordisk A/S· Source
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751· Phase 3· BioNTech SE· Source
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· Phase 3· Eli Lilly and Company· Source
Contact: Suk Joon Chang (principal investigator)
Recruiting
Smart Angioplasty Research Team-Coronary CT Angiography Versus Standard Care as Follow-up Strategies in High-Risk Patients After PCI (SMART-CARE)
NCT07009418· Samsung Medical Center· Source
Contact: Hong-Seok Lim, MD,PhD
Recruiting
Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease
NCT07027072· Phase 2· NeuroBiogen Co., Ltd· Source
Contact: Soyoung Moon, Professor
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· Phase 3· Pfizer· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
NCT06824168· Phase 2· Daiichi Sankyo· Source
Active, not recruiting
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
NCT06736990· Phase 2· Calluna Pharma AS· Source
Active, not recruiting
Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization
NCT06767345· Phase 4· Korea University Anam Hospital· Source
Recruiting
ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74
NCT06714513· Phase 1· Quratis Inc.· Source
Contact: Kwang Joo Park, MD, PhD
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357· Phase 3· Biogen· Source
Contact: US Biogen Clinical Trial Center
Enrolling by invitation
Evaluation of the Impact of Dietary Education and Intervention on Gout Patients Receiving Urate-Lowering Therapy
NCT07834840· Sung Keon Cho· Source
Not yet recruiting
Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry
NCT06843421· Korea University· Source
Contact: Seong Hee Kang, MD., PhD.
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355· Phase 3· BioNTech SE· Source
Recruiting
SB17170 Phase 2 Trial in IPF Patients
NCT06747923· Phase 2· SPARK Biopharma· Source
Contact: Joo Hun Park, M.D.
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· Phase 2/3· BioNTech SE· Source
Active, not recruiting
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824· Phase 3· Genmab· Source
Active, not recruiting
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
NCT06430866· Phase 3· Amgen· Source
Active, not recruiting
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
NCT06311721· Phase 3· Amgen· Source
Active, not recruiting
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142· Phase 3· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Source
Recruiting
Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia
NCT06184009· Phase 2· Jae Wook Lee· Source
Contact: Juyeon Lee, Professor
Active, not recruiting
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
NCT06449209· Phase 2· BioNTech SE· Source
Active, not recruiting
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
NCT06161441· Phase 2· Regeneron Pharmaceuticals· Source
Active, not recruiting
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06445023· Phase 3· Celldex Therapeutics· Source
Recruiting
Study of WAL0921 in Patients With Glomerular Kidney Diseases
NCT06466135· Phase 2· Walden Biosciences· Source
Contact: Michelle Skupien
Recruiting
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273· Phase 2· Allogene Therapeutics· Source
Contact: Seong Huyn Jeong, MD (principal investigator)
Recruiting
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210· Phase 3· Daiichi Sankyo· Source
Contact: Principal Investigator
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995· Phase 3· Eli Lilly and Company· Source
Contact: Hyun-Jun Kim (principal investigator)
Recruiting
Fractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease
NCT05829889· Seung-Jung Park· Source
Contact: Myoung Ho Yoon, MD

Showing 50 of 106.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Coronary artery disease10 recruiting
Lung cancer10 recruiting
Head and neck cancer3 recruiting
Atrial fibrillation2 recruiting
Colorectal cancer2 recruiting
Gastric and oesophageal cancer2 recruiting
Heart failure2 recruiting
Idiopathic pulmonary fibrosis2 recruiting
IgA nephropathy2 recruiting
Lupus (SLE)2 recruiting
Obesity2 recruiting
Ovarian cancer2 recruiting
Stroke2 recruiting
Type 2 diabetes2 recruiting
Acute lymphoblastic leukaemia1 recruiting
Acute myeloid leukaemia1 recruiting
Alopecia areata1 recruiting
Alzheimer disease1 recruiting
Bladder cancer1 recruiting
Childhood cancers1 recruiting
Chronic rhinosinusitis with nasal polyps1 recruiting
Chronic spontaneous urticaria1 recruiting
Dermatomyositis and polymyositis (myositis)1 recruiting
Diffuse large B-cell lymphoma1 recruiting
Fatty liver disease (MASLD/MASH)1 recruiting
Follicular lymphoma1 recruiting
Gout1 recruiting
High blood pressure1 recruiting
Kidney cancer1 recruiting
Liver and biliary tract cancer1 recruiting
Melanoma1 recruiting
Mild cognitive impairment1 recruiting
Nephrotic syndrome1 recruiting
Spinal cord injury1 recruiting
Systemic sclerosis (scleroderma)1 recruiting
Triple-negative breast cancer1 recruiting
Tuberculosis1 recruiting

Closed trials

Withdrawn
Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis
NCT06886009· Boehringer Ingelheim· Source
Completed
Feasibility Study of 'SuperBrain BOOM' for Mild Cognitive Impairment Patients
NCT07101380· Ajou University School of Medicine· Source
Completed
Evaluation of SCALE PET Software for Quantitative Brain PET Analysis in Alzheimer's Disease
NCT07417540· NEUROPHET· Source
Completed
A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
NCT06921759· Phase 3· Eli Lilly and Company· Source
Completed
Early Delirium Prediction Via Serial EEG Trajectories and Machine Learning
NCT07536854· Ajou University School of Medicine· Source
Completed
Cognitive Therapy Software for Improving Cognitive Function for Patients With Mild Cognitive Impairment
NCT06264557· Rowan· Source
Completed
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
NCT06066528· Phase 3· Boehringer Ingelheim· Source
Completed
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
NCT06066515· Phase 3· Boehringer Ingelheim· Source
Terminated
Study of GS-0272 in Participants With Rheumatoid Arthritis
NCT06031415· Phase 1· Gilead Sciences· Source
Completed
A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases
NCT05960708· Phase 1· Yuhan Corporation· Source
Completed
To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
NCT05483907· Phase 2· Bridge Biotherapeutics, Inc.· Source
Completed
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
NCT05583526· Phase 3· Pfizer· Source
Completed
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
NCT05523167· Phase 2/3· argenx· Source
Completed
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
NCT05174221· Phase 1· Takeda· Source
Completed
Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity
NCT04998136· Phase 3· Novo Nordisk A/S· Source
Completed
A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus
NCT05411016· Phase 1· Kyowa Kirin Co., Ltd.· Source
Completed
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
NCT05379634· Phase 2· Janssen Research & Development, LLC· Source
Completed
The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
NCT05162586· Phase 2· EMD Serono Research & Development Institute, Inc.· Source
Completed
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
NCT05067634· Phase 3· SK Life Science, Inc.· Source
Completed
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05014815· Phase 2· BeiGene· Source
Terminated
Study of INCB086550 in Select Solid Tumors
NCT04629339· Phase 2· Incyte Corporation· Source
Completed
Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
NCT05065970· Phase 2· HI-Bio, A Biogen Company· Source
Completed
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
NCT04903314· Phase 1· SK Life Science, Inc.· Source
Completed
Efficacy and Safety of a Voltage-Guided Stepwise Strategy for Pulmonary Vein Isolation
NCT07354737· Ajou University School of Medicine· Source
Completed
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
NCT04499924· Phase 2/3· Seagen Inc.· Source
Completed
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
NCT04338399· Phase 3· Adlai Nortye Biopharma Co., Ltd.· Source
Completed
Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
NCT04505436· Phase 2· Hanmi Pharmaceutical Company Limited· Source
Completed
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
NCT04392154· Phase 3· Eli Lilly and Company· Source
Completed
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
NCT04248829· Phase 3· Yuhan Corporation· Source
Completed
A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy
NCT03499704· Phase 4· Celltrion Pharm, Inc.· Source
Completed
Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia
NCT04700436· Phase 4· Seoul National University Hospital· Source
Terminated
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
NCT04032704· Phase 2· Seagen Inc.· Source
Completed
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
NCT03899259· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
NCT03596866· Phase 3· Takeda· Source
Completed
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03734029· Phase 3· Daiichi Sankyo· Source
Completed
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
NCT03777657· Phase 3· BeiGene· Source
Completed
Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
NCT03678753· Phase 3· SK Life Science, Inc.· Source
Completed
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
NCT03523585· Phase 3· Daiichi Sankyo· Source
Completed
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
NCT03377491· Phase 3· NovoCure Ltd.· Source
Completed
Avelumab in First-line NSCLC (JAVELIN Lung 100)
NCT02576574· Phase 3· EMD Serono Research & Development Institute, Inc.· Source
Completed
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
NCT02273375· Phase 3· Canadian Cancer Trials Group· Source
Recruiting
Observational Study for Left Main Disease Treatment
NCT01341327· Seung-Jung Park· Source
Contact: Seung-Jung Park, MD, PhD

Site data: ClinicalTrials.govUpdated 15 Nov 2026

Report an error